Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021. The on-demand presentation will start on January 11 at 6:00 a.m. E.T., accessible via the company's website. Dynavax focuses on developing and commercializing vaccines, with its first product, HEPLISAV-B®, approved in the U.S. for hepatitis B prevention in adults. The company is also advancing vaccine adjuvants for COVID-19 and other diseases.

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021.

The on demand presentation will be available, beginning Monday, January 11, 2021 at 6:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2021-conference-301202218.html

SOURCE Dynavax Technologies

FAQ

When is Dynavax presenting at the H.C. Wainwright Virtual BioConnect 2021 Conference?

Dynavax will present at the H.C. Wainwright Virtual BioConnect 2021 Conference from January 11-14, 2021.

What will Dynavax CEO Ryan Spencer discuss at the conference?

Ryan Spencer will provide insights on Dynavax's vaccine development and commercialization efforts during his presentation.

Is the Dynavax presentation available for on-demand viewing?

Yes, the Dynavax presentation will be available on-demand starting January 11, 2021, at 6:00 a.m. E.T.

What is the ticker symbol for Dynavax Technologies?

The ticker symbol for Dynavax Technologies is DVAX.

What is HEPLISAV-B® and its significance for Dynavax?

HEPLISAV-B® is Dynavax's first commercial product, approved in the U.S. for the prevention of hepatitis B infection in adults.